Table 2.
Characteristics of treated patients (N = 143)
| Total | DCF (n = 30) No. (%) | ECF (n = 113) No. (%) | P value | ||
|---|---|---|---|---|---|
| Age (years) | Median (range) | 143 | 58 (22–75) | 59 (20–76) | .40 |
| Gender | Female | 50 | 11 (36.7%) | 39 (34.5%) | .83 |
| Male | 93 | 19 (63.3%) | 74 (65.5%) | ||
| Performance status (ECOG) | 0 | 121 | 27 (90.0%) | 94 (83.2%) | .46 |
| 1 | 17 | 3 (10.0%) | 14 (12.4%) | ||
| 2 | 5 | 5 (4.4%) | |||
| Stage at diagnosis | Locally advanced | 46 | 8 (26.7%) | 38 (33.6%) | .47 |
| Metastatic | 97 | 22 (73.3%) | 75 (66.4%) | ||
| Site of primary tumor | Stomach | 113 | 23 (76.7%) | 90 (79.6%) | .75 |
| Lower esophageal | 7 | 1 (3.3%) | 6 (5.3%) | ||
| GEJ | 23 | 6 (20.0%) | 17 (15.0%) | ||
| Histology | Well differentiated | 33 | 6 (20.0%) | 27 (23.9%) | .97 |
| Moderately differentiated | 31 | 7 (23.3%) | 24 (21.2%) | ||
| Poorly differentiated | 70 | 15 (50.0%) | 55 (48.7%) | ||
| Unclassified | 1 | 1 (0.9%) | |||
| Undifferentiated | 8 | 2 (6.7%) | 6 (5.3%) | ||
| Presence of HP at presentation | Yes | 111 | 23 (76.7%) | 88 (77.9%) | .85 |
| No | 11 | 3 (10.0%) | 8 (7.1%) | ||
| Not available | 21 | 4 (13.3%) | 17 (15.0%) | ||
| Time between first symptom(s) and diagnosis (months) | Median (range) | 143 | 6.0 (2–12) | 6.0 (1–12) | .27 |
| Number of chemotherapy cycles | Median (range) | 143 | 6 (1–8) | 6 (1–8) | .56 |
Abbreviations: DCF = docetaxel, cisplatin, and 5-fluorouracil; ECF = epirubicin, cisplatin, and 5-fluorouracil; ECOG = Eastern Cooperative Oncology Group; GEJ = gastroesophageal junction; HP = Helicobacter pylori infection.